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Abstract
Background: Lung disease progression is variable among cystic fibrosis (CF) patients and depends on DNA mutations
in the CFTR gene, polymorphic variations in disease modifier genes, and environmental exposure. The contribution of
genetic factors has been extensively investigated, whereas the mechanism whereby environmental factors modulate the
lung disease is unknown. In this project, we hypothesized that (i) reiterative stress alters the epigenome in CF-affected
tissues and (ii) DNA methylation variations at disease modifier genes modulate the lung function in CF patients.
Results: We profiled DNA methylation at CFTR, the disease-causing gene, and at 13 lung modifier genes in nasal
epithelial cells and whole blood samples from 48 CF patients and 24 healthy controls. CF patients homozygous for the
p.Phe508del mutation and ≥18-year-old were stratified according to the lung disease severity. DNA methylation was
measured by bisulfite and next-generation sequencing. The DNA methylation profile allowed us to correctly classify 75%
of the subjects, thus providing a CF-specific molecular signature. Moreover, in CF patients, DNA methylation at specific
genes was highly correlated in the same tissue sample. We suggest that gene methylation in CF cells may be co-
regulated by disease-specific trans-factors. Three genes were differentially methylated in CF patients compared with
controls and/or in groups of pulmonary severity: HMOX1 and GSTM3 in nasal epithelial samples; HMOX1 and EDNRA in
blood samples. The association between pulmonary severity and DNA methylation at EDNRA was confirmed in blood
samples from an independent set of CF patients. Also, lower DNA methylation levels at GSTM3 were associated with the
GSTM3*B allele, a polymorphic 3-bp deletion that has a protective effect in cystic fibrosis.
Conclusions: DNA methylation levels are altered in nasal epithelial and blood cell samples from CF patients. Analysis of
CFTR and 13 lung disease modifier genes shows DNA methylation changes of small magnitude: some of them are a
consequence of the disease; other changes may result in small expression variations that collectively modulate the lung
disease severity.
Keywords: DNA methylation, Co-methylation, Nasal epithelial cells, Cystic fibrosis, Modifier gene, Pulmonary function,
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Background
Environmental factors (i.e., nutrition, maternal diet,
pollution, exercise, and lifestyle) influence the pheno-
type of living organisms by shaping their epigenome
and consequently by affecting gene expression [1].
Change in the epigenome could contribute to human
diseases and might explain the incomplete penetrance
of some mutations as well as the age of appearance
of symptoms [2].
Cystic fibrosis (CF) is a monogenic disease that results
from mutations in the cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene that encodes a cAMP-
regulated epithelial chloride channel. This life-threatening
disease is characterized by recurrent pulmonary infections,
chronic inflammation, pancreatic insufficiency, and male
infertility. Although multiple organs are affected, morbidity
and mortality are mainly due to the lung disease because
chronic infections and abnormal inflammation lead to
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progressive airway destruction. Lung disease progression is
variable among CF patients and depends on the combin-
ation of three factors: (i) DNA mutations in the CFTR
gene, (ii) polymorphic variations in other genes, and (iii)
environmental exposure.
The contribution of genetic factors to CF phenotype has
been extensively investigated by previous studies [3]. DNA
mutations have been classified in six groups, depending
on the mechanism by which they alter CFTR synthesis,
traffic, and function [4]. The p.Phe508del mutation (dele-
tion of the phenylalanine residue at position 508) leads to
protein misfolding and degradation. This mutation is very
frequent in the Caucasian population (it is homozygous in
40% of CF patients) and is generally, but not always, asso-
ciated with a severe phenotype. Genetic and transcrip-
tomic studies have provided a rich compilation of genes
that can modify the CF outcome and are responsible for
the disease variability [5–7]. Genotype-phenotype correla-
tions in CF twins showed that environmental factors also
contribute to pulmonary function variation in CF patients
[3, 8], but the precise mechanism whereby these factors
modulate the lung disease is unknown. The respiratory
system is exposed to environmental stimuli (e.g., chemi-
cals, dust, bacteria, or viruses). Of note, CF airway tissues
are exposed not only to these external pollutants but also
to the high cellular stress generated by the inflammatory
and immune responses. Oxidative products generated by
the inflammatory response can alter DNA methylation in
both directions. Oxidation of 5-methylcytosines and 8-
guanosines hinders MBP and DNMT1 binding, favoring
loss of DNA methylation [9]. Oxidative compounds pro-
duced by the neutrophilic response generate halogenated
cytosines that, because they mimic CpG methylation, are
recognized by the methyl-binding proteins (MBP) and by
the DNMT1 and, hence, favor methylation gain [10, 11].
In CF airway tissues, the oxidative stress is high and the
neutrophil response particularly strong. Therefore, we hy-
pothesized that (i) reiterative stress alters the epigenome
in CF-affected tissues and (ii) DNA methylation changes
at CF modifier genes contribute to the lung function
variations observed in CF patients. To test our hypoth-
eses, we profiled DNA methylation in healthy controls
and homozygous p.Phe508del CF patients stratified
according to their pulmonary function. We analyzed
CFTR, the disease-causing gene, and 13 lung modifier
genes. Ten genes were identified by genetic association
studies. They encode proteins involved in inflammatory
and immune responses (TLR2, TLR5, TGFβ2, and IFRD1),
oxidative stress (HMOX1, GSTM1, and GSTM3), bronch-
oconstriction (EDNRA), and mucus structure and hydra-
tion (MUC5AC and ENaCγ). Three genes (ATF1, DUOX2,
and YY1) were differentially expressed in nasal epithelial
cells collected from CF patients characterized by extreme
disease phenotypes [5].
A major hurdle when addressing the epigenome effects
on disease severity is to gather appropriate tissue samples
from the patients. Here, we used nasal epithelial cells
(NEC), which are an informative model to study DNA
methylation in airway diseases [12], and blood cells be-
cause most of the analyzed genes encode proteins that are
involved in the inflammatory and immune responses.
Results
DNA methylation analysis in NEC and blood samples
The study was carried out in NEC and blood samples
from the METHYLCF cohort that includes 48 CF pa-
tients and 24 healthy controls (Table 1). Using bisulfite
and next-generation sequencing (BS-NGS), we analyzed
DNA methylation at CpG islands associated with CFTR
and 13 CF lung modifier genes (Table 2). The analyzed
regions ranged from 133 to 264 bp, included from 5 to
26 CpG dinucleotides, and were less than 1550 bp away
from the transcriptional start site (TSS), except for the
MUC5AC CpG island that was in the gene body (from
exon 35 to intron 35–36). In each region, we measured
the methylation at single CpG dinucleotides and the
mean DNA methylation. DNA methylation was profiled
in 72 blood samples (all patients and controls) and in 63
NEC samples (39 CF patients and all healthy controls).
Six patient NEC samples did not provide enough
genomic DNA and three samples were reserved for further
analyses. To evaluate the repeatability of the BS-NGS
methylation analyses, we duplicated the measurements of
the 14 genes in four CF patients in both tissues. The esti-
mated standard deviation of DNA methylation reached
0.44 in the logit unit used for variance homogenization.
This is quite high because the standard deviation of the
methylation around its mean value was of the order of 0.43
in blood and of 0.52 in NEC samples, for both the CF
patients and the healthy controls. Nevertheless, the correl-
ation between DNA methylation data in the two independ-
ent experiments was excellent (Spearman’s r = 0.97, p = 0)
(Additional file 1: Figure S1).
In the control samples, DNA methylation was very
high at MUC5AC (median value 95% in blood and 83%
in NEC samples), high at TLR5 (median value 38% in
blood and 26% in NEC samples), and low in the other
genes (<20% for both sample types) (Additional file 2:
Figure S2). A partial least square discriminant analysis
of the mean DNA methylation (the descriptors were
the percentage of DNA methylation at the 14 genes in
blood and NEC samples) provided 75% of correct clas-
sification of CF patients versus controls (Fig. 1). The
percentage of correct classification was slightly lower
when we used DNA methylation data from NEC sam-
ples alone (72%) and even lower with data from blood
samples (69%) (Fig. 1).
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Table 1 Demographic and relevant clinical features of CF patients and controls
Discovery set (METHYLCF) Replication set (FrGMC)
C (n = 24) CF (n = 48) Mild (n = 23) Intermediary (n = 13) Severe (n = 12) CF (n = 30) Mild (n = 18) Severe (n = 12)
Age, yeara 37 26 34 25.5 22 24.5 27.0 23.5
Sex, M:F 13:11 32:16 17:6 11:2 4:8 19:11 14:4 5:7
BMI (kg/m2)a 20.9 22.1 20.5 19.8 19.9 21.4 18.0
Weight (kg)a 60.0 62.0 60.0 52.0 56.0 60.0 45.5
Height (cm)a 170 170 171 168 168.0 170.0 161.5
FEV1%
a 48.0 64.8 48.0 41.5 91.0 102.0 24.0
FVC %a 74.0 87.0 67.0 66.5 98.5 105.0 46.0
% PI 100 100 100 100
% Diabetes 36.7 47.8 23.0 33.3
% Atopy 28.3 31.8 23.1 27.3
% P. Aeruginosa 93.9 91.3 100 90.9
% MRSA 34.1 22.7 30.8 60.0
% Aspergillus 18.2 26.1 14.3 20.0
PI pancreatic insufficiency
aMedian
Table 2 CFTR and CF modifier genes
Gene
symbol













chr7:117,479,627-117,479,759 10 133 1(−)
DUOX2 Dual oxidase 2 chr15:45,114,541-45,114,722 11 182
EDNRA Endothelin receptor
type A











chr1:109,740,573-109,740,793 9 221 1(–) 3(–) 4(–) 5(–) 6(–)
7(–) 8(–)
4(–) 9(–)




chr7:112,450,883-112,451,040 12 158 10(–)




chr19:41,353,542-41,353,740 19 199 10(–)
TLR2 Toll-like receptor 2 chr4:153,684,576-153,684,704 12 129 8(–)
TLR5 Toll-like receptor 5 chr1:223,142,813-223,142,967 8 155 8(–)
YY1 Yin-Yang 1
transcription factor
chr14:100,240,497-100,240,751 26 255 8(–) 22(–)
aHuman Genome GRCh38/hg38 build
bnb of CpG in the analyzed region
cPosition of the CpG in the analyzed sequence. Plus signs mean hypermethylated and minus signs mean hypomethylated CpG in CF patients
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Besides the mean DNA methylation, we calculated
the DNA methylation at individual CpG dinucleotides
(n = 194 in the fourteen genes). Forty-two CpG sites
(21%) in nine genes were differentially methylated be-
tween patients and controls in at least one tissue
(Table 2). Specifically, 19 CpG sites were differentially
methylated in NEC samples and 29 in blood samples.
In NEC samples, most CpG sites were more methyl-
ated in CF patients than in controls (12 out of 19).
Conversely, in blood samples, most of the differen-
tially methylated CpG sites (24 out of 29) were less
methylated in CF patients than in controls.
DNA methylation correlations in CF cells
Next, we looked for inter-tissue (DNA methylation of a
gene in both cell types) and intra-tissue (DNA methyla-
tion of two genes in the same tissue) correlations. Data
from CF patients and controls were analyzed separately
using stringent criteria (Bonferroni-controlled family-
wise error rate (FWER) = 10%). Correlations were calcu-
lated using the mean DNA methylation of each gene
region. Interestingly, DNA methylation at GSTM3 was
highly correlated in NEC and blood samples collected
from the same individuals, both in controls and CF pa-
tients (Fig. 2). This finding suggests that methylation
level at GSTM3 is under genetic control.
Moreover, a few intra-tissue correlations were found
in genomic DNA from CF patients (Fig. 2). Specifically,
in NEC samples, we found two co-methylation modules:
(i) the DNA methylation level of TLR5 correlated with
that of MUC5AC, CFTR, and HMOX1 and (ii) the DNA
methylation level of HMOX1 correlated with that of
EDNRA and CFTR. In blood samples, the DNA methyla-
tion level of HMOX1 correlated with that of CFTR and
with TLR2.
In control samples, no intra-tissue correlations were sig-
nificant with a FWER of 10%. All genes were expressed in
the tissue where their co-methylation was found, except
Fig. 1 (Top) Partial least square (PLS) discriminant analyses of CF patients and controls in blood, NEC, and both tissue samples and the percentage of
correct classification of the subjects in each analysis. v1,v2 are the scores on the first two PLS axes. (Bottom) The descriptors are mean DNA methylation
of 14 genes
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for CFTR that was not expressed in blood samples. Thus,
gene expression does not seem to be an essential pre-
requisite for co-methylation. We assessed gene expression
by RT-PCR using NEC and blood mRNAs from two
healthy individuals (data not shown).
HMOX1 was differentially methylated in NEC and blood
samples from CF patients
Next, we focused on genes that were differentially
methylated in CF patients or groups of patients.
HMOX1 was previously identified as a CF modifier
gene by genetic association studies [13]. We measured
DNA methylation at the CpG island that overlaps exon
2 (Fig. 3). Using the mean DNA methylation in the re-
gion, we found that HMOX1 was differentially methyl-
ated in NEC samples (Student p = 0.018) and blood cell
samples (Wilcoxon p = 0.009) of CF patients compared
with controls, but the direction of the methylation
change was not the same in the two tissue models
(Fig. 4a, b). Moreover, DNA methylation was associated
with lung disease severity (ANOVA p = 0.052 in NEC
samples; Kruskal-Wallis p = 0.035 in blood samples)
(Fig. 4c, d). One CpG dinucleotide (CpG#2) was more
methylated than the other four CpG in the region (ap-
proximately 30% compared with <10%) (Fig. 4e, f ).
CpG#2 was differentially methylated in CF patients
compared with controls in both tissues (Bonferroni cor-
rected q = 0 in blood and q = 2.7 10−3 in NEC) and was
associated with pulmonary severity in blood samples
(Kruskal-Wallis p = 0.0019).
DNA methylation at HMOX1 was not associated with nearby
polymorphisms
Previous studies showed that two polymorphic sequences
in the 5′ untranslated region of HMOX1 were associated
with lung function in airway diseases. Specifically, the
minor allele of the A(-413)T variant (rs2071746) was asso-
ciated with CF lung disease severity in two independent
cohorts [13] (Fig. 3). Next to this single-nucleotide poly-
morphism (SNP), the length of a (GT)n microsatellite cor-
related with pulmonary severity in airway (emphysema
and COPD) and cardiovascular diseases [14, 15] (Fig. 3).
Long microsatellites (>32 repeats) were associated
with lower levels of transcription in vitro and with an
adverse clinical phenotype in patients [16]. Because
these polymorphisms were close (600 bp upstream) to
the region analyzed in this study, we asked whether
they affected DNA methylation. We assessed the
A(-413)T SNP and the microsatellite length in CF
patients and healthy volunteers of the METHYLCF
cohort and found that DNA methylation levels (mean
methylation of the amplicon and methylation at
CpG#2) in NEC and blood samples did not correlate
with any genotype (Spearman’s correlation test)
(Additional file 3: Table S2).
DNA methylation at HMOX1 was not associated with a
significant change of gene expression
Next, we asked whether DNA methylation at HMOX1 af-
fected gene expression. In blood cells, DNA methylation
A)
B)
Fig. 2 The matrices show inter-tissue (mean DNA methylation of a gene
in both cell types) and intra-tissue (mean DNA methylation of two genes
in one tissue) correlations in controls (a) and CF patients (b). The prefix
n- or b- in front of the gene name indicates that DNA methylation was
measured in NEC or blood samples, respectively. Significant correlations
(black square) were calculated using Spearman’s test with a Bonferroni-
controlled family-wise error rate (FWER) = 10%
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and gene expression were analyzed in samples collected
from the same individuals. HMOX1 was not differentially
expressed in CF patients compared with controls (Wil-
coxon p = 0.11) or in patients stratified according to the
lung disease severity (Kruskal-Wallis p = 0.39) (Fig. 5a).
Also, expression and DNA methylation levels (mean
methylation of the amplicon and methylation at CpG#2)
were not correlated, be it in the whole cohort (Spear-
man’s r = 0.09, p = 0.48) or separately in the control
(Spearman’s r = −0.14, p = 0.62) and in the CF (Spearman’s
r = 0.08, p = 0.58) populations (Fig. 5b).
RNA could not be extracted from the NEC samples of
the METHYLCF cohort because the whole amount of
cells had to be used to isolate genomic DNA. Therefore,
to determine the expression levels in NEC samples, we
inspected data from three publicly available transcrip-
tomic studies [5, 17, 18]. HMOX1 was not differentially
expressed in CF compared with control NEC. The only
study that compared mild versus severe CF patients was
not informative for this gene [5].
EDNRA was differentially methylated but not differentially
expressed in CF blood samples
EDNRA encodes a G protein-coupled receptor that, fol-
lowing binding to endothelin, triggers cellular prolifera-
tion and contraction of smooth muscle cells. In CF
airways, higher level of endothelin may contribute to the
pulmonary phenotype [19]. In the METHYLCF cohort,
EDNRA was less methylated in CF than in control blood
samples (Wilcoxon p = 0.017) and DNA methylation
level correlated with the lung disease severity (Kruskal-
Wallis p = 0.028) (Fig. 6a, b). The DNA methylation at
individual CpG sites was homogeneous, close to the
mean methylation in the region (Fig. 6c).
Gene expression was not detectable in blood cells,
even in CF samples where EDNRA was less methylated.
Thus, we concluded that loss of DNA methylation at
EDNRA was a consequence rather than a cause of lung
disease severity.
DNA methylation levels at GSTM3 were associated with
lung disease severity and correlated with the GSTM3*B
allele
The mean DNA methylation at GSTM3 was not signifi-
cantly different in CF and control samples; however, it was
associated with CF lung disease severity in NEC samples
(ANOVA p = 0.016) (Fig. 7a). DNA methylation at individ-
ual CpG sites was homogeneous (Fig. 7b).
Previous studies showed that various polymorphisms
of the GST(M) genes contribute to lung disease severity
in CF patients [20] and that GST activity may modulate
P. aeruginosa lung infection [21]. Of note, the
GSTM3*B allele, a 3-bp deletion that has a protective
effect in CF patients, is 6.1 kb downstream of the region
analyzed in this study. To determine whether this poly-
morphic sequence affected DNA methylation levels, we
Fig. 3 Top, HMOX1 exon-intron structure and position of the CpG island. Bottom, HMOX1 partial genomic sequence showing exons 1 and 2 (gray
background) and introns (white background). Also shown, the five CpG (in white on black background) where we measured DNA methylation, the
major “A” allele of SNP rs2071746 (white on black background) and the polymorphic (GT)n microsatellite (underlined) in exon 2
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genotyped patients and controls for the micro-deletion
(Additional file 3: Table S2). Interestingly, in both NEC
and blood samples, DNA methylation levels at GSTM3
correlated with the presence of the GSTM3*B allele
(Spearman’s NEC r = −0.43 p = 5 10−4; blood r = −0.42
p = 2.8 10-4). DNA methylation levels in homozygous
GSTM3*B carriers were lower than in heterozygous
carriers, where they were lower than in homozygous
GSTM3*A carriers (Fig. 7c, d).
Replication of DNA methylation analysis in an independent
set of CF patients
To replicate data obtained in the METHYLCF cohort,
we selected 30 additional p.Phe508del homozygous pa-
tients with severe (n = 12) or mild lung disease (n = 18)
from an independent CF cohort enrolled by the French
CF Gene Modifier Consortium (FrGMC) [22]. Of note,
the phenotype of this set of patients was more extreme
than that of the METHYLCF cohort (Table 1). Genomic
DNA being available for blood and not for NEC cells,
we decided to replicate blood differentially methylated
regions (EDNRA and HMOX1), leaving replication of NEC
regions for future studies. DNA methylation was measured
by locus-specific pyrosequencing. To analyze EDNRA, we
used a pyrosequencing assay located 350 bp downstream of
the region that was targeted by BS-NGS. In the replication
set of patients, DNA methylation at EDNRA was signifi-
cantly associated with lung disease severity (Kruskal-Wallis
p = 0.047) (Additional file 4: Figure S3). DNA methylation
in mild CF patients was higher than in controls (Wilcoxon
p = 0.023) and slightly higher than in severe patients (not
significant). Overall, EDNRA DNA methylation levels by
pyrosequencing were higher than those obtained by




Fig. 4 DNA methylation at HMOX1. The dot plots represent the mean DNA methylation of HMOX1 in CF patients compared with controls in NEC (Student
p= 0.018) (a) and in blood (Wilcoxon p= 0.009) samples (b). DNA methylation levels depended on pulmonary severity (NEC, ANOVA p= 0.052 (c); blood,
Kruskal-Wallis p = 0.035 (d)). The horizontal line indicates the median in each group. The heat maps represent the DNA methylation at five
CpG dinucleotides in NEC (e) and blood (f) samples. White lines represent missing data. CFM mild CF patient, CFI intermediary CF patient,
CFS severe CF patient
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Potapova et al. [23] who compared the two methods
and showed a trend towards higher values in the
range between 0 and 20% DNA methylation.
For HMOX1, all tested primers failed to provide a
linear pyrosequencing signal in the region of interest.
Discussion
In this study, we provide the first DNA methylation pro-
file using tissue samples collected from CF patients. We
measured DNA methylation at CpG islands associated
with CFTR and 13 CF modifier genes. DNA methylation
A) B)
Fig. 5 HMOX1 gene expression in blood samples. a The box plots represent the relative expression of HMOX1 in CF patients with different lung
disease and controls (Kruskal-Wallis p = 0.39). CFM mild CF patient, CFI intermediary CF patient, CFS severe CF patient. b Correlation between gene
expression and mean DNA methylation levels in blood samples from CF patients and controls. Whole cohort (Spearman’s r = 0.09, p = 0.48); controls
(Spearman’s r = −0.14, p = 0.62); CF patients (Spearman’s r = 0.08, p = 0.58)
A) B)
C)
Fig. 6 DNA methylation at EDNRA in blood samples. a The dot plots represent the mean DNA methylation of EDNRA in CF patients compared
with controls (Wilcoxon p = 0.017). b DNA methylation at EDNRA correlated with pulmonary severity (Kruskal-Wallis p = 0.028). The horizontal line
indicates the median in each group. c The heat map represents DNA methylation at 21 CpG dinucleotides. CFM mild CF patient, CFI intermediary
CF patient, CFS severe CF patient
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levels were altered not only in NEC, which are directly
affected by the disease (CF patients often have rhinitis
and nasal polyposis), but also in blood cells where CFTR
is not expressed. By combining the DNA methylation
data obtained in NEC and blood cells, we correctly clas-
sified 75% of the subjects, distinguishing homozygous
p.Phe508del CF patients from controls. This finding sug-
gests that DNA methylation variations in specific genes
may provide a CF-specific molecular signature.
Our study has also disclosed a number of genes whose
methylation seemed to be co-regulated in CF samples.
Concomitant DNA methylation changes in two or more
genes have been already described in solid tumors, in-
cluding in lung adenocarcinomas [24] and in sputum
samples of asthmatic smokers [25]. More recently, van
Eijk et al. identified networks of co-methylation and co-
expression modules in blood samples collected from
healthy individuals [26]. In this genome-wide analysis,
co-methylation and co-expression modules contained
few overlapping genes, but several pairs of methylation
and expression modules were significantly correlated
[26]. Moreover, because they were enriched in gene
ontology categories, these modules were considered bio-
logically relevant. The actual mechanism responsible for
their generation is unknown, however, the existence of
factors that affect DNA methylation and gene expression
acting in trans at the module level was hypothesized [26].
In our study, using stringent conditions, we observed gene
co-methylation exclusively in patient samples. Therefore,
we suggest the involvement of trans-acting factors that
are specifically activated by the disease, namely by the
oxidative stress and the inflammatory and immune
responses. A genome-wide DNA methylation analysis
of CF samples is required to better understand this
phenomenon.
By comparing patients and controls, we found significant
DNA methylation variations at two CF modifier genes:
HMOX1 (in NEC and blood cells) and EDNRA (in blood
cells). Moreover, the DNA methylation level at three genes
(GSTM3 in NEC and HMOX1 and EDNRA in blood
samples) was associated with lung disease severity. The
association between pulmonary severity and DNA methyla-
tion at EDNRA was replicated using blood samples from an
independent set of CF patients. The magnitude of the
methylation changes in lung severity modifier genes was
small. Three lines of evidence show that small epigenomic
changes can be biological meaningful. First, many epi-
demiological studies showed that the environment induces
A) B)
C) D)
Fig. 7 DNA methylation at GSTM3. The mean DNA methylation at GSTM3 depended on pulmonary severity (ANOVA p = 0.016) (a). The heat maps
represent DNA methylation at nine CpG dinucleotides in NEC samples; white lines represent missing data (b). Low methylation levels correlated with
the GSTM3*B allele both in blood (Spearman’s r = −0.42, p = 3 10−4) (c) and NEC samples (Spearman’s r =−0.43, p = 5 10−4) (d). CFM mild CF patient, CFI
intermediary CF patient, CFS severe CF patient. The horizontal line in the dot plots indicates the median in each group. A/A homozygous GSTM3*A, A/B
heterozygous, B/B homozygous GSTM3*B
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small epigenetic changes associated with a clinical
outcome. In patients affected by chronic obstructive
pulmonary disease and exposed to fine particulate
matter (PM2.5) constituents, hypomethylation of the
NOS2A gene (about −1.5%) was associated with a higher
(about +18%) fractional concentration of exhaled nitric
oxide (FeNO), a biomarker of airway inflammation [27].
In patients with type 2 diabetes mellitus (T2DM), a CpG
dinucleotide in the first intron of the FTO gene was hypo-
methylated (−3.35%) and the odds of belonging to the
T2DM group increased by 6.1% for every 1% decrease in
DNA methylation [28]. Second, experimental studies in
animals showed the impact of small methylation changes
on gene expression. In the offspring of rat fed with a
protein-restricted diet during pregnancy, a small decrease
of DNA methylation in the promoter of PPARα was asso-
ciated with an increase of gene expression [29]. Third, a
genome-wide expression analysis in patients affected by
type 2 diabetes mellitus showed that small expression
changes in multiple genes belonging to the same pathway
had a bigger impact than a high-fold change in a single
gene [30, 31]. Collectively, these findings lead us to
suggest that small DNA methylation variations in lung
modifier genes can impact cystic fibrosis severity.
HMOX1 encodes a protein that is important for iron
homeostasis and cell protection from oxidative damage
during stress. Activating and repressive factors regulate
the HMOX1 basal expression by interacting with the
promoter and various stimuli (i.e., heme, cadmium, and
oxidative stress) switch on its induced expression via
binding to responsive elements [32]. Of note, the CpG
island targeted in our DNA methylation analysis con-
tains an HMOX1 hydrogen peroxide-responsive element
[14]. CF tissues are exposed to continuous stress by the
immune and inflammatory responses. Here, we found
that HMOX1 was differentially methylated both in blood
and NEC samples from CF patients compared with con-
trols, but the direction of the methylation change was
not the same in the two tissue models. One possible
explanation is that DNA methylation levels result from a
balance between the burden of halogenic compounds
produced by the inflammatory response (especially by
neutrophils) that favors methylation gain [10, 11] and
other oxidative products responsible for methylation loss
[9]. The contribution of these opposing factors is likely
to be different in blood and NEC because NEC are
directly affected by cystic fibrosis. In addition, in NEC
samples, the increase of DNA methylation at the pro-
moter of HMOX1 was non-monotonic in CF patients
stratified according to the lung disease severity. The
intensity of the inflammatory response and of the oxida-
tive stress in the airway tissues varies among patients and
correlates with the lung disease [33, 34]. The proportion of
oxidative products changing DNA methylation in opposite
directions may be variable in stratified CF patients so that
the final ratio results in a U-shaped curve. The possible
effect of DNA methylation on HMOX1 transcription de-
serves further analysis. In NEC samples, the small amount
of cells did not allow us to carry DNA methylation and
gene expression analysis on the same samples. In blood
samples, we failed to demonstrate a significant impact of
DNA methylation on expression, possibly due to the lack
of statistical power of the present cohort.
EDNRA encodes a G protein-coupled receptor that,
following ligation to endothelin, causes contraction of
smooth cells. Previous genetic studies showed an associ-
ation between EDNRA DNA polymorphisms and pulmon-
ary disease in four independent cohorts of CF patients
[19]. Also, a functional study showed that an allele that is
deleterious for the lung function resulted in higher
EDNRA mRNA levels in human tracheal smooth muscle
cells [19]. Our study shows that EDNRA was hypomethy-
lated in CF patients and DNA methylation levels were
associated with pulmonary disease severity in blood cells.
Because EDNRA transcripts were not detected in control
nor in CF samples, we conclude that loss of DNA methy-
lation had no impact on gene expression and was probably
a consequence rather than a cause of lung disease severity.
Compelling evidence shows that DNA methylation is
affected not only by environmental but also by genetic
factors. Of note, methylation levels at 2–7% of CpG sites
are associated with cis-DNA variants and may provide
the molecular mechanisms for the associated quantita-
tive trait locus [26]. In the present study, we realized
that two differentially methylated regions mapped close
to polymorphic sequences that have been previously
shown to be associated with the pulmonary function in
airway diseases: two DNA variants were in the 5′ un-
translated region of HMOX1 and the third one was in
the body of GSTM3. Since we found no correlation
between DNA methylation levels and two polymorphic
sequences in HMOX1, we suggest that DNA methylation
and the two polymorphisms are independently associ-
ated with lung function. This result should be validated
in an independent cohort. Conversely, two findings in
our study suggest that DNA methylation in the GSTM3
gene is under genetic control. First, DNA methylation at
GSTM3 was highly correlated with the presence of the
GSTM3*B allele both in NEC and blood samples. Sec-
ond, we found a high positive correlation between
GSTM3 DNA methylation levels in the blood and NEC
samples from the same individuals. These results are
consistent with a previous study showing that diplotypes
in the GSTM3 gene predicted DNA methylation levels at
five CpG dinucleotides scattered in the gene, outside the
region we analyzed [35]. The GSTM3*B allele, a 3-bp de-
letion in intron 6, is associated with higher level of
GSTM3 mRNA and protein expression [36]. To explain
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this association, it was proposed that the 3-bp deletion
generates a binding site for the transcription factor YY1
[37]. We hypothesize that upon activation by YY1 or
another transcription factor, the GSTM3*B intronic se-
quence binds to the gene promoter via a chromatin loop
and causes a reduction in the DNA methylation level in the
same region. The GSTM3 protein conjugates various toxic
compounds to glutathione, thus, similarly to HMOX1, has
a protective effect in cells, and is particularly beneficial to
CF damaged tissues.
The present study has limitations. We analyzed 48 CF
patients and 24 healthy controls. Confirmatory studies
should be carried out on a larger number of patients.
DNA methylation was analyzed in 14 lung modifier genes
and restricted to the promoter regions. Future studies
should cover the whole genome including other genic and
intergenic regulatory regions (enhancers, insulators, etc).
We could not analyze gene expression in NEC samples
because the whole amount of cells had to be used for
DNA extraction.
Conclusions
In summary, we showed that DNA methylation was
altered in nasal epithelial and blood samples from CF pa-
tients and, using stringent conditions, we observed mod-
ules of gene co-methylation exclusively in patient samples.
Through the analysis of 13 lung disease-modifiers genes,
we found DNA methylation changes of small magnitude
in two genes (HMOX1 and EDNRA). DNA methylation
was associated with pulmonary severity in three genes
(HMOX1, GSTM3, and EDNRA) and with a polymorphic
deletion that has a protective effect in cystic fibrosis at
one gene (GSTM3). Some of these small DNA methylation
changes are a consequence of the disease. Other
changes may result in small expression variations that
collectively and over time modulate the lung disease
severity. Genome-wide epigenomic, transcriptomic and
genomic analyses are needed to further understand how
genetic and epigenetic factors contribute to the large
spectrum of lung disease severity in cystic fibrosis.
Methods
Study cohorts
The study was approved by the local Institutional Review
Board (CPP Sud Méditerranée III, Nîmes #2013.02.01bis).
Informed written consent was obtained from all partici-
pants. Table 1 lists the demographic and relevant clinical
features of two cohorts. CF patients were homozygous for
the p.Phe508del mutation and ≥18-year-old. Exclusion cri-
teria for CF patients included lung transplantation and
pulmonary exacerbation during sample collection.
The METHYLCF cohort includes 48 CF patients and
24 healthy controls with no history of airway diseases or
allergy. It was enrolled in four CF centers in the South
of France. CF patients were stratified into three groups
based on the severity of the lung disease and mainly
using the FEV1% predicted: mild (48% of patients),
intermediary (27%), and severe (25%). Patients with
FEV1% predicted values that corresponded to the top
and bottom quartiles were classified as mild and severe,
respectively [38]. CF patients of age ≥34 years were
considered mild because of their long survival. The age
distribution did not differ between patients and con-
trols (Wilcoxon p = 0.30). The male-to-female ratio was
slightly, but not significantly, higher in CF patients than
in controls (χ2 p = 0.22).
From the already available FrGMC cohort (French Ethical
Board, CPP #2004/15) [22], a replication set of CF patients
(12 patients with severe and 18 patients with mild pulmon-
ary disease) was selected. They were stratified using the
same criteria as for the METHYLCF cohort.
Biological samples
Biological samples were collected from the METHYLCF
cohort, whereas blood genomic DNA was already avail-
able for the replication FrGMC cohort.
Nasal epithelial cells were collected from the inferior tur-
binate using nasal curettes (Rhino-probe, Arlington) after
nebulization with 5% xylocaine (Astrazeneca, France). NEC
were collected from both nostrils, pooled together in 1 ml
RNA protect Cell Reagent (#76526 Qiagen), and then
shipped to the handling center at room temperature.
Whole blood samples were collected in EDTA (5 ml) and
in PAXgene (2.5 ml) tubes (#762165, Becton Dickinsen) for
DNA and RNA extraction, respectively.
DNA extraction
NEC collected in RNAprotect Cell Reagent (#76526
QIAGEN) were treated with 1 mg/mL RNAse. Genomic
DNA was extracted using the QIAamp DNA Micro Kit
(#56304, QIAGEN) as previously described [39]. The
mean DNA yield was 5.1 ± 2.8 μg in controls and 3.9 ±
3.1 μg in CF patients (range 0 to 12.4 μg). DNA yield
was not significantly different between groups (Wilcoxon
p = 0.19).
Genomic DNA was extracted from whole blood sam-
ples using the Flexigene DNA kit (#51206, QIAGEN) ac-
cording to the manufacturer’s recommendations.
RNA extraction
RNA was extracted from whole blood samples using the
PAXgene Blood RNA kit (#762124, PreAnalytix), accord-
ing to the manufacturer’s recommendations.
Bisulfite conversion
NEC and blood DNA samples were treated with sodium
bisulfite as previously described [40].
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DNA methylation analysis by amplicon sequencing
Fusion primers were designed to amplify 133 to 264 bp-
long amplicons in the region of interest (Additional file 5:
Table S1). Each forward primer contained a MID (Multi-
plex Identifiers, Roche) to allow computational screening of
each sample. PCR products were obtained using the Pyro-
Mark PCR kit (#978703, QIAGEN), and 10 μM forward
and reverse primers in a 25-μl final volume. PCR conditions
were 95 °C for 15 min, followed by 94 °C for 30 s, the
annealing temperature for 30s, 72 °C for 30 s for 45 cycles,
and then 72 °C for 10 min. Amplicons were purified with
the QIAquick PCR Purification Kit (#28106 QIAGEN)
and quantified using a NanoDrop 2000 Spectrophotom-
eter (Thermo Scientific) and a Qubit 2.0 fluorometer
(Life Technologies). In each sequencing run, 112 puri-
fied amplicons were pooled in equimolar amounts.
Emulsion PCR and subsequent bidirectional sequencing
were done according to the GS Junior emPCR Amplifica-
tion Method Manual-Lib-A (#05996520001, Roche) and
GS Junior Sequencing Method Manual (#05996554001,
Roche), respectively.
Sequence analysis
We measured DNA methylation using bisulfite and next-
generation sequencing (BS-NGS). To filter and order the
raw sequencing data, we developed a pipeline. The script
works in a Galaxy environment and includes four steps: (i)
a barcode splitter to separate sequences per sample; (ii) a
sequence trimming to remove all the MID (multiplex
identifiers, Roche) and adaptor sequences; (iii) a barcode
splitter to separate sequences per gene; and (iv) analysis of
fasta/bam files with BiQAnalyzer HT [41]. BiQAnalyzer
HT removes non-fully converted sequences and deter-
mines the methylation status of each CpG site within
amplicons. It provides a text file where each CpG site is
either 1 (methylated) or 0 (unmethylated). A minimal con-
version rate of 0.97 was used. Before filtering, the number
of reads per analyzed amplicon ranged from 9 to 2704.
We retained only the BS-NGS measurements for which
the number of sequences was large enough as to have
either a coefficient of variation of the mean methylation
percentage smaller than 5% or a standard deviation not
higher than 1% (the first condition is too stringent for very
small methylation percentages). After filtering, 95% of the
reads were in the interval [98; 1460].
DNA methylation analysis by pyrosequencing
PCR products were amplified using the PyroMark PCR
Kit ((#978703, QIAGEN) in 25 μL reaction volume. For
EDNRA, the pool of forward and reverse primers (one of
which was biotin-labeled at the 5′) as well as the se-
quencing primer were from the Hs_EDNRA_02_PM
PyroMark CpG Assay (#978746, QIAGEN, Hilden,
Germany). The PCR program was 94 °C for 15 min,
followed by 94 °C 30 s, 56 °C for 30 s, 72 °C for 30 s dur-
ing 45 cycles, and 72 °C for 10 min. PCR products were
purified using 1 μL Streptavidin Sepharose HP™ (#17-
5113-01, GE Healthcare) and a PyroMark Q24 Worksta-
tion. Pyrosequencing reactions were performed in a
PyroMark Q24 (QIAGEN) using the PyroMark Gold
Q24 reagents (#970802, QIAGEN) according to the
manufacturer’s instructions. Before the assays, we tested
the signal linearity using mixtures of methylated and
unmethylated genomic DNA (0, 20, 40, 60, 80, and
100%); standard errors were from three replicates.
Genotyping
HMOX1 (GT)n microsatellite
Using blood genomic DNA, we amplified a 113–135-bp
DNA fragment spanning the (GT)n microsatellite with a
FAM-labeled sense primer (5′-AGAGCCTGCAGCTTCT-
CAGA-3′) and an unlabeled reverse primer (5′-ACAAA
GTCTGGCCATAGGAC-3′). The PCR program was 94 °C
30 s, 57 °C 90 s, 72 °C 90 s for 30 cycles. PCR products
were analyzed using an ABI 3130xl Genetic Analyzer
(Applied Biosystem), and the microsatellite size was mea-
sured with the Gene Mapper software (Applied Biosystem).
HMOX1 SNP rs2071746
A 139-bp PCR fragment surrounding the A(-413)T SNP
(rs2071746) was amplified with the following program:
95 °C 30 s, 64 °C 30 s, 72 °C 30 s for 35 cycles. Primers
were forward 5′-GCAGAGGATTCCAGCAGGTG-3′
and reverse 5′-CAGGCGTCCCAGAAGGTTCC-3′. After
purification with the QIAquick kit (QIAGEN) and labeling
with the Big Dye Terminator (Life Technologies), DNA
was sequenced using an ABI 3130xl Genetic Analyzer
(Applied Biosystem).
GSTM3 *A and GSTM3*B alleles
A 202-bp PCR fragment was amplified using primers 5′-
GCTACCTGGACAACTGAAAC-3′ and 5′-CGGTTC
TGATCCAAGATATC-3′ and the following program:
95 °C 5 min, then (95 °C 30 s, 56 °C 30 s, 72 °C 1 min)
for 25 cycles and 72 °C 15 min. PCR products were ana-
lyzed using an ABI 3130xl Genetic Analyzer (Applied Bio-
system) and their size measured with the Gene Mapper
software (Applied Biosystem).
Gene expression
For reverse transcription, 500 ng of total blood RNA
from each sample was added to Rnase-free water (final
volume 8 μl) followed by DNase I treatment for 15 min
at room temperature. Samples were then added to a mix
containing 4 μl of first strand 5× buffer, 2 μl of 10× di-
thiothreitol, 1 μl of 10 mM dNTP mix, 300 ng/μl of hex-
aprimer (random primers), 20–40 U/μl of RNasin®
enzyme (Promega), and 200 U/μl of MMLV-RT enzyme
Magalhães et al. Clinical Epigenetics  (2017) 9:19 Page 12 of 15
(Life Technology). The reverse transcription reaction pro-
gram consisted of three steps: 10 min at 25 °C, 50 min at
37 °C, and 15 min at 70 °C. mRNA expression was mea-
sured using a LightCycler 480 real-time PCR system and
SYBR Green I Master mix® (Roche Diagnostics) (primers
are listed in Additional file 5: Table S1). Standard curves
were generated for each run by serial dilution of control
cDNA. Gene expression levels were expressed as ratios
relative to that of reference genes (GAPDH for HMOX1
and TBP for EDNRA). Real-time PCR reactions were done
in duplicate in two independent reverse transcriptions.
Statistical analysis
For a given gene, the mean methylation of each individual
site as well as the mean methylation percentage over all
sites were left for statistical analysis. To homogenize the
variance of the mean methylation percentage (which is
maximal at 50% and zero at 0 or 100%), we worked with
its logit transformation.
To evaluate the repeatability of the BS-NGS methylation
analyses, we duplicated the measurements corresponding
to the ng = 14 genes of interest for 4 CF patients in
the nt = 2 tissues (blood and NEC) with 106 degrees
of freedom (instead of 4 × ng × nt = 112 due to few
missing values).
To compare the mean methylation level of a given gene
in a given tissue between controls and CF patients, and
across the whole cohort stratified according to the severity
of the lung disease (i.e., controls, mild, intermediary, and
severe CF patients), depending on the statistical features
of the data (normality or not, homoscedasticity or not),
we used either parametric tests (i.e., Student, Welch, and
analysis of variance tests) or non-parametric tests (i.e.,
Wilcoxon and Kruskal-Wallis tests). P values <0.05 were
considered statistically significant. To compare the methy-
lation status of the individual CpG sites between con-
trols and CF patients, we used Fisher’s exact test. To take
the multiplicity of the hypotheses into account, we used
Bonferroni’s correction and a family-wise error rate
(FWER) of 5% was considered significant.
The ability of the 14 genes in both tissues to discriminate
between controls and CF patients was further evaluated
using a partial least square discriminant analysis. The de-
scriptors were the normalized mean methylation levels in
one of the tissues or both. The PLS response was discrete
with two levels, −1 for controls and +1 for CF patients:
positive PLS estimates correspond to a classification into
the control class and negative ones to a classification into
the CF patients class, hence a percentage of correct
classification.
We studied the correlations of the mean methylation
levels of the genes in both tissues using Spearman’s
non-parametric correlation coefficient. To take the
multiplicity of the hypotheses into account, we used
Bonferroni’s correction and a FWER of 10% was con-
sidered significant.
The expression ratios of HMOX1 in blood obtained
with PCR were log transformed before their mean was
taken. Because the resulting values were non-Gaussian,
the expression levels between controls and stratified or
unstratified CF patients were compared with Kruskal-
Wallis’ and Wilcoxon’s tests. The correlation with the
mean methylation level and the methylation status of
the individual CpG sites was analyzed with Spearman’s
coefficient.
Spearman’s coefficient was used to test the correlation of
lung function (characterized by degree of severity, FEV1%
predicted and FVC) with CF patient genotypes at GSTM3,
(homozygous GSTM3*A, GSTM3*A/GSTM3*B and homo-
zygous GSTM3*B) and at HMOX1 (rs2071746 A/A, A/T
and T/T; and the (GT)n microsatellite length where we
considered both the largest or the smallest n of the two
alleles). Multivariate regression models were also used
to correct for factors such as demographic and clinical
data (Table 1).
Additional files
Additional file 1: Figure S1. Correlation between DNA methylation data
in two independent experiments (Spearman’s r = 0.97 p = 0). (PNG 113 kb)
Additional file 2: Figure S2. DNA methylation distribution at 14
analyzed genes in CF and control samples. (PDF 212 kb)
Additional file 3: Table S2. Distribution of HMOX1 and GSTM3
genotypes in CF patients and controls (DOCX 39 kb)
Additional file 4: Figure S3. DNA methylation analysis at EDNRA in an
independent set of CF patients. DNA methylation at EDNRA was associated
with pulmonary severity in blood samples collected from this independent
set of severe (CFS) and mild (CFM) CF patients (Kruskal-Wallis p = 0.047). CF
patients were from the FrGMC cohort; controls were from the METHYLCF
cohort. The mean DNA methylation was measured by pyrosequencing.
(PNG 72 kb)
Additional file 5: Table S1. Primers. (DOCX 49 kb)
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